Noam Solomon
Noam Solomon, PhD, is co-founder and CEO of Immunai, which combines single-cell biology, machine learning and experimental validation to map the immune system and improve drug discovery and development. Its platform builds on AMICA, a cell-level immune knowledge base combining multiomic and clinical data, which the company uses with pharmaceutical partners to predict how patients will respond to treatments and to guide preclinical and clinical decisions. He holds two PhDs, one in mathematics and one in computer science, and conducted postdoctoral research in MIT's Department of Mathematics. He entered Tel Aviv University at 14 and earned his bachelor's degree in computer science by 19.
Info about the founder
Noam Solomon, PhD, is co-founder and CEO of Immunai, which combines single-cell biology, machine learning and experimental validation to map the immune system and improve drug discovery and development. Its platform builds on AMICA, a cell-level immune knowledge base combining multiomic and clinical data, which the company uses with pharmaceutical partners to predict how patients will respond to treatments and to guide preclinical and clinical decisions. He holds two PhDs, one in mathematics and one in computer science, and conducted postdoctoral research in MIT's Department of Mathematics. He entered Tel Aviv University at 14 and earned his bachelor's degree in computer science by 19.